$-0.44 EPS Expected for Ocular Therapeutix, Inc. (OCUL) as of May, 4

April 16, 2018 - By Anthony Romero

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Corporate Logo

Earnings report for Ocular Therapeutix, Inc. (NASDAQ:OCUL) is anticipated On May, 4., according to Zacks. EPS of $-0.44 is 24.14 % up from 2017’s $-0.58 EPS. Last quarter $-0.44 EPS was reported. Analysts predicts 0.00 % EPS growth this quarter. On during the last trading session the stock decreased $0.08 or 1.23%, reaching $6.4.Currently Ocular Therapeutix, Inc. is downtrending after 32.37% change in last April 16, 2017. OCUL has also 79,815 shares volume. OCUL underperformed the S&P 500 by 43.92%.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Ratings Coverage

Total analysts of 4 have positions in Ocular Therapeutix (NASDAQ:OCUL) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since October 23, 2017 according to StockzIntelligence Inc Ocular Therapeutix has 7 analyst reports. On Thursday, March 8 Cantor Fitzgerald maintained the shares of OCUL in report with “Buy” rating. On Friday, March 9 the stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) earned “Buy” rating by H.C. Wainwright. On Tuesday, November 7 the stock has “Buy” rating by Cantor Fitzgerald. On Thursday, March 8 the rating was maintained by BTIG Research with “Buy”. On Wednesday, November 8 the stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) has “Buy” rating given by H.C. Wainwright. On Friday, January 19 the firm has “Buy” rating given by BTIG Research. On Monday, October 23 the stock of Ocular Therapeutix, Inc. (NASDAQ:OCUL) earned “Buy” rating by Guggenheim.

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology.The company has $238.58 million market cap. The Company’s product pipeline candidates utilize its platform to provide differentiated drug delivery solutions that are designed to reduce the complexity and burden of current drop or injection regimens by creating sustained release one-time or several-month dosage forms.Last it reported negative earnings. The company's lead product candidate, DEXTENZA 0.4 mg for intracanalicular use has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: